^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TBio-6517

    i
    Other names: TBio-6517, RIVAL-01, TAK-605
    Associations

    News

    Trials
    Company:
    Turnstone Biologics
    Drug class:
    CTLA4 antagonist, IL-12 stimulant, FLT3 stimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P1/2, N=27, Terminated, Turnstone Biologics, Corp. | Trial completion date: Dec 2023 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Jan 2023; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Oncolytic virus • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • TBio-6517
    almost2years
    RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, Turnstone Biologics, Corp. | Recruiting --> Active, not recruiting | N=138 --> 27 | Trial completion date: Jul 2025 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Jun 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Oncolytic virus • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • TBio-6517
    almost3years
    RAPTOR: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Turnstone Biologics, Corp. | Trial completion date: Dec 2022 --> Jul 2025 | Trial primary completion date: Aug 2022 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Oncolytic virus
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • TBio-6517
    over3years
    RAPTOR: Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (clinicaltrials.gov)
    P1/2, N=114, Recruiting, Turnstone Biologics, Corp. | N=84 --> 114
    Clinical • Enrollment change • Combination therapy • Oncolytic virus
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • TBio-6517
    over4years
    RAPTOR: Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (clinicaltrials.gov)
    P1/2, N=84, Recruiting, Turnstone Biologics, Corp. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • Oncolytic virus
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • TBio-6517
    almost5years
    RAPTOR: Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (clinicaltrials.gov)
    P1/2, N=84, Not yet recruiting, Turnstone Biologics, Corp.
    Clinical • New P1/2 trial • Combination therapy • Oncolytic virus
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • TBio-6517